# US 2013/0259888 A1 · Means of controlling infection persistence of helicobacter pylori

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0259888 A1
- Document ID: US20130259888A1
- Status: Published application
- Kind: A1
- Application number: 13/806,084
- Filed: 2011-06-24
- Published: 2013-10-03
- Earliest claimed: 2010-06-25
- Assignees: Ondek Pty. Ltd.
- Inventors: Mohammed Benghezal; Tobias Schoep; Alma Fulurija; Douglas E. Berg; Barry J. Marshall
- Web page: https://patentgrep.com/patent/US20130259888A1

## CPC

- A61K 39/105: {Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter}
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- C12N 1/36: Adaptation or attenuation of cells
- C12N 9/80: acting on amide bonds in linear amides {(3.5.1)}
- C12Y 305/01005: Urease (3.5.1.5)
- A61K 2039/522: {avirulent or attenuated}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to a means of controlling infection persistence of Helicobacter pylori (H. pylori). In particular, the present invention relates to an isolated, genetically modified Helicobacter pylori comprising a functional urease, wherein the contiguous amino acid sequence between amino acid 529 and amino acid 555 of SEQ ID NO:1 is altered to produce said modified Helicobacter pylori which is unable to establish or maintain a persistent infection.

## Claims

### Claim at position 1

1-21. (canceled)

### Claim 22

An isolated, genetically modified Helicobacter pylori comprising a functional urease, wherein the contiguous amino acid sequence between amino acid 529 and amino acid 555 of SEQ ID NO:1 is altered to produce said modified Helicobacter pylori that is unable to establish or maintain a persistent infection.

### Claim 23 (depends on 22)

The genetically modified Helicobacter pylori cell of claim 22, wherein the amino acid sequence between amino acid 529 to amino acid 555 of SEQ ID NO:1 is altered by deletion, mutation, or insertion.

### Claim 24 (depends on 22)

The genetically modified Helicobacter pylori cell of claim 22, wherein the amino acids that are altered are selected from the group consisting of 547, 548, and 549 of SEQ ID NO:1.

### Claim 25 (depends on 23)

The genetically modified Helicobacter pylori of claim 23, wherein the mutation comprises a conservative or non-conservative amino acid change.

### Claim 26 (depends on 22)

The genetically modified Helicobacter pylori of claim 22, wherein the alteration comprises an insertion of one or more amino acids.

### Claim 27 (depends on 26)

The genetically modified Helicobacter pylori of claim 26, wherein the insertion comprises between 10 and 100 amino acids.

### Claim 28 (depends on 22)

The genetically modified Helicobacter pylori of claim 22, further comprising a nucleic acid molecule encoding at least one heterologous antigen, or a functional fragment thereof.

### Claim 29 (depends on 28)

The genetically modified Helicobacter pylori of claim 28, wherein the heterologous antigen, or a functional fragment thereof is from a pathogenic microorganism.

### Claim 30 (depends on 29)

The genetically modified Helicobacter pylori of claim 29, wherein the pathogenic microorganism from which the nucleic acid encoding the heterologous antigen is obtained is selected from the group consisting of a virus, a bacterium, a protozoan, and a fungus.

### Claim 31 (depends on 28)

The genetically modified Helicobacter pylori of claim 28, wherein the heterologous antigen is selected from the group consisting of a human immunodeficiency virus (HIV) antigen, an HTLV antigen, an SIV antigen, an RSV antigen, a PIV antigen, an HSV antigen, a CMV antigen, an Epstein-Barr virus antigen, a Varicella-Zoster virus antigen, a mumps virus antigen, a measles virus antigen, an influenza virus antigen, a poliovirus antigen, a rhinovirus antigen, a hepatitis A virus antigen, a hepatitis B virus antigen, a hepatitis C virus antigen, a Norwalk virus antigen, a togavirus antigen, an alphavirus antigen, a rubella virus antigen, a rabies virus antigen, a Marburg virus antigen, an Ebola virus antigen, a papilloma virus antigen, a polyoma virus antigen, a metapneumovirus antigen, a coronavirus antigen, a Vibrio cholerae antigen, a Plasmodium falciparum antigen, a Plasmodium vivax antigen, a Plasmodium ovate antigen, a Plasmodium malariae antigen, a Plasmodium knowlesi antigen, a Streptococcus pneumoniae antigen, Streptococcus pyogenes antigen, a Helicobacter pylori antigen, a Streptococcus agalactiae antigen, a Neisseria meningitidis antigen, a Neisseria gonorrhoeae antigen, a Corynebacterium diphtheriae antigen, a Clostridium tetani antigen, a Bordetella pertussis antigen, a Haemophilus antigen, a Chlamydia antigen, and an Escherichia coli antigen.

### Claim 32 (depends on 26)

The genetically modified Helicobacter pylori of claim 26, wherein the amino acid insertion encodes a heterologous antigen or a functional fragment thereof.

### Claim 33 (depends on 32)

The genetically modified Helicobacter pylori of claim 32, wherein the heterologous antigen is selected from the group consisting of a human immunodeficiency virus (HIV) antigen, an HTLV antigen, an SIV antigen, an RSV antigen, a PIV antigen, an HSV antigen, a CMV antigen, an Epstein-Barr virus antigen, a Varicella-Zoster virus antigen, a mumps virus antigen, a measles virus antigen, an influenza virus antigen, a poliovirus antigen, a rhinovirus antigen, a hepatitis A virus antigen, a hepatitis B virus antigen, a hepatitis C virus antigen, a Norwalk virus antigen, a togavirus antigen, an alphavirus antigen, a rubella virus antigen, a rabies virus antigen, a Marburg virus antigen, an Ebola virus antigen, a papilloma virus antigen, a polyoma virus antigen, a metapneumovirus antigen, a coronavirus antigen, a Vibrio cholerae antigen, a Plasmodium falciparum antigen, a Plasmodium vivax antigen, a Plasmodium ovate antigen, a Plasmodium malariae antigen, a Plasmodium knowlesi antigen, a Streptococcus pneumoniae antigen, Streptococcus pyogenes antigen, a Helicobacter pylori antigen, a Streptococcus agalactiae antigen, a Neisseria meningitidis antigen, a Neisseria gonorrhoeae antigen, a Corynebacterium diphtheriae antigen, a Clostridium tetani antigen, a Bordetella pertussis antigen, a Haemophilus antigen, a Chlamydia antigen, and an Escherichia coli antigen.

### Claim 34 (depends on 22)

An immunogenic composition comprising the genetically modified Helicobacter pylori of claim 22, and a pharmaceutically acceptable carrier.

### Claim 35 (depends on 34)

The immunogenic composition of claim 34, further comprising an adjuvant.

### Claim 36 (depends on 34)

A method for protecting a mammal against an infection with a pathogenic microorganism, the method comprising administering an immunologically effective amount of the immunogenic composition of claim 34.

### Claim 37

A method of controlling the ability of Helicobacter pylori to establish a persistent infection, the method comprising altering the contiguous amino acid sequence between amino acid 529 and amino acid 555 of SEQ ID NO:1 to produce a modified UreB subunit of urease, wherein said urease retains de-acidification function, but said Helicobacter pylori is unable to establish or maintain a persistent infection.

### Claim 38

A method of vaccinating an mammal against a Helicobacter pylori infection, the method comprising administering to said mammal an isolated, genetically modified Helicobacter pylori comprising a functional urease, wherein the contiguous amino acid sequence between amino acid 529 and amino acid 555 of SEQ ID NO:1 is altered to produce said modified Helicobacter pylori that is unable to establish or maintain a persistent infection.

### Claim 39

An immunogenic composition for use in vaccinating a mammal, the composition comprising an isolated, genetically modified Helicobacter pylori comprising a functional urease, wherein the contiguous amino acid sequence between amino acid 529 and amino acid 555 of SEQ ID NO:1 is altered to produce said modified Helicobacter pylori that is unable to establish or maintain a persistent infection and a pharmaceutically acceptable carrier.

### Claim 40

A peptide vaccine consisting essentially of amino acid 529 to amino acid 555 of SEQ ID NO:1 and a pharmaceutical carrier.

### Claim 41 (depends on 40)

The peptide vaccine of claim 40, further comprising an adjuvant.

### Claim 42 (depends on 40)

A method of vaccinating a subject against Helicobacter pylori infection, the method comprising administering to said subject the peptide vaccine of claim 40.
